- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00972881
Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer (EXCITE)
EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for Locally Advanced Rectal Cancer (North West Clinical Oncology Group-04 on Behalf of the NCRI Rectal Cancer Subgroup)
RATIONALE: Drugs used in chemotherapy, such as capecitabine and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy, cetuximab, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase I/II trial is studying the side effects of giving capecitabine and irinotecan hydrochloride together with cetuximab and radiation therapy and to see how well it works in treating patients undergoing surgery for locally advanced rectal cancer.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
OBJECTIVES:
- To assess the downstaging effectiveness and tolerability of neoadjuvant chemoradiotherapy comprising capecitabine, irinotecan hydrochloride, cetuximab, and radiotherapy in patients with locally advanced rectal cancer.
OUTLINE: This is a multicenter study.
Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-6 and irinotecan hydrochloride IV over 1 hour once weekly in weeks 2-5. Patients also undergo pelvic radiotherapy once daily and receive oral capecitabine twice daily on days 1-5 in weeks 2-6.
Patients undergo surgery 8 weeks after completion of chemoradiotherapy.
After completion of study treatment, patients are followed up at 6, 12, 24, and 36 months.
Peer Reviewed and Funded or Endorsed by Cancer Research United Kindom (UK).
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
England
-
Leeds, England, Royaume-Uni, LS16 6QB
- Yorkshire Regional Clinical Trials & Research Unit
-
Manchester, England, Royaume-Uni, M20 4BX
- Christie Hospital
-
Merseyside, England, Royaume-Uni, CH63 4JY
- Clatterbridge Centre for Oncology
-
Preston, England, Royaume-Uni, PR2 9HT
- Rosemere Cancer Centre at Royal Preston Hospital
-
-
Wales
-
Rhyl, Denbighshire, Wales, Royaume-Uni, LL 18 5UJ
- Cancer Research UK and University College London Cancer Trials Centre
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the rectum
MRI-defined locally advanced disease, as defined by 1 of the following:
- Mesorectal fascia involvement
- Mesorectal fascia threatened (tumor ≤ 1 mm from mesorectal fascia)
- Any T3 tumor < 5 cm from anal verge
- No evidence of metastatic disease
PATIENT CHARACTERISTICS:
- ECOG or WHO performance status 0-1
- ANC ≥ 1.5 x 10^9/L
- Platelet count ≥ 100 x 10^9/L
- Serum bilirubin < 1.25 times upper limit of normal (ULN)
- Serum transaminase(s) < 3 times ULN
- Serum alkaline phosphatase < 5 times ULN
- Estimated glomerular filtration rate > 50 mL/min
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Fit to receive all study treatments
- Able to comply with oral medication
- No comorbidity or coagulation problem that would deem the patient unsuitable for surgery
- No pre-existing condition that would preclude radiotherapy (e.g., fistulas, severe ulcerative colitis [particularly patients currently taking sulfasalazine], Crohn's disease, prior adhesions)
- No current or impending rectal obstruction (unless a defunctioning stoma is present) or metallic colonic rectal stent in situ
- No significant small bowel delineated within the radiotherapy fields
- No pelvic sepsis
- No gastrointestinal disorder that would interfere with oral therapy or oral bioavailability
- No uncontrolled cardiac, respiratory, or other disease that would preclude study therapy or informed consent
- No serious medical or psychiatric disorder that would preclude study therapy or informed consent
- No known dihydropyrimidine dehydrogenase deficiency
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy
- No prior radiotherapy to the pelvis
- No concurrent participation in other studies, except genetic studies (e.g., NSCCG-National Study of Colorectal Cancer Genetics)
- No concurrent St. John wort
- No other concurrent cytotoxic treatment or radiotherapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Histologically confirmed R0 resection rate
Délai: Week 14 (6 weeks after treatment complete)
|
Week 14 (6 weeks after treatment complete)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Radiotherapy compliance
Délai: Weeks 2, 3, 4, 5 & 6
|
Radiotherapy treatment and dosage is captured on weekly CRFs from week 2-6
|
Weeks 2, 3, 4, 5 & 6
|
Grade 3 or 4 toxicity as assessed by NCI CTCAE v3.0
Délai: Baseline, week 1- 10, week 12 & 14 then at 6, 12, 24 & 36 months follow up
|
Adverse events are recorded weekly on CRFs from week 1 of treatment until 4 weeks post treatment, then at 1 month post surgery and specified time points during long term follow up at 6, 12, 24 & 36 month intervals.
|
Baseline, week 1- 10, week 12 & 14 then at 6, 12, 24 & 36 months follow up
|
Pathological complete response
Délai: Week 14 (surgery conducted 6 weeks from end of treatment)
|
Week 14 (surgery conducted 6 weeks from end of treatment)
|
|
Post-operative morbidity
Délai: Week 14
|
Week 14
|
|
Long-term morbidity
Délai: Week 14, then at 6, 12, 24 & 36 months follow up
|
Week 14, then at 6, 12, 24 & 36 months follow up
|
|
Disease-free survival
Délai: Baseline, week 1- 10, week 12, 14 & then at 6, 12, 24 & 36 months follow up
|
Baseline, week 1- 10, week 12, 14 & then at 6, 12, 24 & 36 months follow up
|
|
Local failure-free survival
Délai: Baseline, weeks 1- 10, weeks 12 & 14 then at 6, 12, 24 & 36 months follow up
|
Baseline, weeks 1- 10, weeks 12 & 14 then at 6, 12, 24 & 36 months follow up
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Simon Gollins, MD, Glan Clwyd Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Tumeurs
- Tumeurs par site
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies gastro-intestinales
- Maladies intestinales
- Tumeurs intestinales
- Maladies rectales
- Tumeurs colorectales
- Tumeurs rectales
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Inhibiteurs de la topoisomérase
- Agents antinéoplasiques immunologiques
- Inhibiteurs de la topoisomérase I
- Capécitabine
- Irinotécan
- Cétuximab
Autres numéros d'identification d'étude
- CDR0000648171
- CRUK-UCL-EXCITE
- EUDRACT-2007-006701-25
- EU-20964
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer rectal
-
National Cancer Institute (NCI)RésiliéCancer rectal de stade III AJCC v8 | Adénocarcinome rectal | Cancer rectal de stade II AJCC v8 | Carcinome rectal localement avancéÉtats-Unis
-
City of Hope Medical CenterRetiréCancer rectal récurrent | Cancer rectal de stade I | Cancer rectal de stade II | Cancer rectal de stade III
-
Mayo ClinicNational Cancer Institute (NCI)ComplétéCarcinome rectal récurrent | Adénocarcinome rectal | Cancer rectal de stade IV AJCC v7 | Cancer rectal de stade IVA AJCC v7 | Cancer rectal de stade IVB AJCC v7États-Unis
-
National Cancer Institute (NCI)RésiliéAdénocarcinome rectal métastatique | Adénocarcinome rectal | Cancer rectal de stade III AJCC v7 | Cancer du rectum de stade IIIA AJCC v7 | Cancer du rectum de stade IIIB AJCC v7 | Cancer du rectum de stade IIIC AJCC v7 | Cancer rectal de stade IV AJCC v7 | Cancer rectal de stade IVA AJCC v7 | Cancer... et d'autres conditionsÉtats-Unis
-
National Cancer Institute (NCI)ComplétéAdénocarcinome rectal | Cancer rectal de stade III AJCC v7 | Cancer rectal de stade II AJCC v7États-Unis
-
National Cancer Institute (NCI)NRG OncologyComplétéAdénocarcinome rectal | Cancer rectal de stade III AJCC v7 | Cancer rectal de stade II AJCC v7États-Unis, Porto Rico
-
M.D. Anderson Cancer CenterRecrutementCancer rectal de stade III AJCC v8 | Cancer du rectum de stade IIIA AJCC v8 | Cancer du rectum de stade IIIB AJCC v8 | Cancer du rectum de stade IIIC AJCC v8 | Cancer rectal de stade IV AJCC v8 | Cancer rectal de stade IVA AJCC v8 | Cancer rectal de stade IVB AJCC v8 | Cancer rectal de stade IVC... et d'autres conditionsÉtats-Unis
-
M.D. Anderson Cancer CenterActif, ne recrute pasAdénocarcinome rectal métastatique | Cancer rectal de stade III AJCC v8 | Cancer du rectum de stade IIIA AJCC v8 | Cancer du rectum de stade IIIB AJCC v8 | Cancer du rectum de stade IIIC AJCC v8 | Cancer rectal de stade IV AJCC v8 | Cancer rectal de stade IVA AJCC v8 | Cancer rectal de stade IVB... et d'autres conditionsÉtats-Unis
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecrutementCancer rectal de stade III AJCC v8 | Cancer rectal de stade II AJCC v8 | Carcinome rectal localement avancéÉtats-Unis, Porto Rico
-
Memorial Sloan Kettering Cancer CenterRecrutementCancer rectal | Adénocarcinome rectal | Adénocarcinome du rectum | Adénocarcinome rectal localement avancé | Adénocarcinome rectal HER2 positifÉtats-Unis
Essais cliniques sur chlorhydrate d'irinotécan
-
New Mexico Cancer Care AllianceWyeth is now a wholly owned subsidiary of PfizerRésilié
-
BayerComplétéOncologie pédiatriqueRoyaume-Uni, France, Espagne, Italie
-
Reema A. PatelRecrutementCancer colorectal | Cancer du pancréasÉtats-Unis
-
PharmaEngineComplétéTumeurs solides réfractairesTaïwan
-
Haibo ZhangRecrutementCancer du poumon à petites cellules (SCLC)Chine
-
UNICANCERBayerRésiliéAdénocarcinome de la jonction gastro-oesophagienne | Adénocarcinome de l'estomacFrance
-
Kentuckiana Cancer InstituteComplétéGliome malinÉtats-Unis
-
Duke UniversityPharmacia; Keryx / AOI Pharmaceuticals, Inc.ComplétéGlioblastome | GliosarcomeÉtats-Unis
-
Baohui HanPas encore de recrutementCancer du poumon à petites cellules au stade étenduChine
-
CSPC Ouyi Pharmaceutical Co., Ltd.InconnueCancer du pancréas avancéChine